Literature DB >> 6991092

A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group.

C A Perez, K Stanley, P Rubin, S Kramer, L Brady, R Perez-Tamayo, G S Brown, J Concannon, M Rotman, H G Seydel.   

Abstract

Entities:  

Mesh：

Year:  1980        PMID： 6991092     DOI： 10.1002/1097-0142(19800601)45:11<2744::aid-cncr2820451108>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  60 in total

1.  A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117.

Authors:  Jeffrey D Bradley; Jennifer Moughan; Mary V Graham; Roger Byhardt; Ramaswamy Govindan; Jack Fowler; James A Purdy; Jeff M Michalski; Elizabeth Gore; Hak Choy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-01       Impact factor: 7.038

2.  Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer.

Authors:  Arya Amini; Jinzhong Yang; Ryan Williamson; Michelle L McBurney; Jeremy Erasmus; Pamela K Allen; Mandar Karhade; Ritsuko Komaki; Zhongxing Liao; Daniel Gomez; James Cox; Lei Dong; James Welsh
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-01       Impact factor: 7.038

Review 3.  Definitive radiotherapy in locally advanced non-small cell lung cancer: dose and fractionation.

Authors:  Nergiz Dağoğlu; Şule Karaman; Alptekin Arifoğlu; Seden Küçücük; Ethem N Oral
Journal:  Balkan Med J       Date:  2014-12-01       Impact factor: 2.021

4.  A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer.

Authors:  Ahmad A Tarhini; Chandra P Belani; James D Luketich; Athanassios Argiris; Suresh S Ramalingam; William Gooding; Arjun Pennathur; Daniel Petro; Kevin Kane; Denny Liggitt; Tony Championsmith; Xichen Zhang; Michael W Epperly; Joel S Greenberger
Journal:  Hum Gene Ther       Date:  2011-02-02       Impact factor: 5.695

Review 5.  50 Years of progress in the systemic therapy of non-small cell lung cancer.

Authors:  Heather Wakelee; Karen Kelly; Martin J Edelman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

6.  Randomized phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancer.

Authors:  Wolfgang Schuette; Maciej J Krzakowski; Bartomeu Massuti; Gregory A Otterson; Richard Lizambri; Helen Wei; Dietmar P Berger; Yuhchyau Chen
Journal:  J Thorac Oncol       Date:  2012-01       Impact factor: 15.609

7.  Dose escalation for unresectable locally advanced non-small cell lung cancer: end of the line?

Authors:  Julian C Hong; Joseph K Salama
Journal:  Transl Lung Cancer Res       Date:  2016-02

8.  The impact of hyperfractionated radiotherapy regimen in patients with non-small cell lung cancer.

Authors:  Georg Holgersson; Michael Bergqvist; Jan Nyman; Even Hoye; Martin Helsing; Signe Friesland; Margareta Holgersson; Lars Ekberg; Charlotte Mörth; Simon Ekman; Thomas Blystad; Sven-Börje Ewers; Britta Löden; Roger Henriksson; Stefan Bergström
Journal:  Med Oncol       Date:  2012-12-18       Impact factor: 3.064

9.  Treatment outcomes of three-dimensional conformal radiotherapy for stage III non-small cell lung cancer.

Authors:  Seung-Gu Yeo; Moon-June Cho; Sun-Young Kim; Seung-Pyung Lim; Ki-Hwan Kim; Jun-Sang Kim
Journal:  Cancer Res Treat       Date:  2005-10-31       Impact factor: 4.679

10.  Comparison of chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer.

Authors:  Hideyuki Harada; Nobuyuki Yamamoto; Toshiaki Takahashi; Masahiro Endo; Haruyasu Murakami; Asuka Tsuya; Yukiko Nakamura; Akira Ono; Satoshi Igawa; Takehito Shukuya; Akihiro Tamiya; Tetsuo Nishimura
Journal:  Int J Clin Oncol       Date:  2009-12-05       Impact factor: 3.402
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.